Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

This study tests vorolanib as a second-line treatment for kidney cancer (renal cell carcinoma) that cannot be surgically removed or has spread to other parts of the body, in patients whose disease progressed on a prior treatment. Vorolanib is a targeted drug that cuts off blood supply to tumors. **You may be eligible if...** - You are 18–80 years old - You have confirmed clear cell kidney cancer (or kidney cancer with clear cell components) - Your cancer has spread or is unresectable - You have already tried one previous treatment that stopped working - Your overall health and organ function are adequate **You may NOT be eligible if...** - You have had more than one prior systemic treatment - You have uncontrolled high blood pressure or significant heart problems - You have brain metastases (cancer spread to the brain) - You have severe liver or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.